Literature DB >> 33732147

Characterization of Mechanical Allodynia and Skin Innervation in a Mouse Model of Type-2 Diabetes Induced by Cafeteria-Style Diet and Low-Doses of Streptozotocin.

Gabriela Castañeda-Corral1, Norma B Velázquez-Salazar1, Arisai Martínez-Martínez2, Juanita N Taboada-Serrano1, Pablo N Núñez-Aragón1, Laura González-Palomares1, Rosa Issel Acosta-González2, Vera L Petricevich1, Juan José Acevedo-Fernández1, Sergio Montes3, Juan Miguel Jiménez-Andrade2.   

Abstract

Background: Painful distal symmetrical polyneuropathy (DPN) is a frequent complication of type-2 diabetes mellitus (T2DM) that commonly presents as neuropathic pain and loss of skin nerve fibers. However, there are limited therapies to effectively treat DPN and many of the current animal models of T2DM-induced DPN do not appear to mirror the human disease. Thus, we validated a DPN mouse model induced by a cafeteria-style diet plus low-doses of streptozotocin (STZ).
Methods: Female C57BL/6J mice were fed either standard (STD) diet or obesogenic cafeteria (CAF) diet for 32 weeks, starting at 8 weeks old. Eight weeks after starting diets, CAF or STD mice received either four low-doses of STZ or vehicle. Changes in body weight, blood glucose and insulin levels, as well as oral glucose- and insulin-tolerance tests (OGTT and ITT) were determined. The development of mechanical hypersensitivity of the hindpaws was determined using von Frey filaments. Moreover, the effect of the most common neuropathic pain drugs was evaluated on T2DM-induced mechanical allodynia. Finally, the density of PGP -9.5+ (a pan-neuronal marker) axons in the epidermis from the hindpaw glabrous skin was quantified.
Results: At 22-24 weeks after STZ injections, CAF + STZ mice had significantly higher glucose and insulin levels compared to CAF + VEH, STD + STZ, and STD + VEH mice, and developed glucose tolerance and insulin resistance. Skin mechanical sensitivity was detected as early as 12 weeks post-STZ injections and it was significantly attenuated by intraperitoneal acute treatment with amitriptyline, gabapentin, tramadol, duloxetine, or carbamazepine but not by diclofenac. The density of PGP-9.5+ nerve fibers was reduced in CAF + STZ mice compared to other groups.
Conclusion: This reverse translational study provides a painful DPN mouse model which may help in developing a better understanding of the factors that generate and maintain neuropathic pain and denervation of skin under T2DM and to identify mechanism-based new treatments.
Copyright © 2021 Castañeda-Corral, Velázquez-Salazar, Martínez-Martínez, Taboada-Serrano, Nuñez-Aragón, González-Palomares, Acosta-González, Petricevich, Acevedo-Fernández, Montes and Jiménez-Andrade.

Entities:  

Keywords:  cafeteria diet.; mechanical allodynia; painful distal polyneuropathy; skin hypersensitivity; skin nerve fibers; type 2 diabetes mellitus

Year:  2021        PMID: 33732147      PMCID: PMC7957928          DOI: 10.3389/fphar.2020.628438

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  63 in total

Review 1.  Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics.

Authors:  Sheila Collins; Tonya L Martin; Richard S Surwit; Jacques Robidoux
Journal:  Physiol Behav       Date:  2004-04

2.  Prevalence of Obesity Among Adults and Youth: United States, 2011-2014.

Authors:  Cynthia L Ogden; Margaret D Carroll; Cheryl D Fryar; Katherine M Flegal
Journal:  NCHS Data Brief       Date:  2015-11

3.  A murine model of type 2 diabetes mellitus developed using a combination of high fat diet and multiple low doses of streptozotocin treatment mimics the metabolic characteristics of type 2 diabetes mellitus in humans.

Authors:  Sayantan Nath; Sankar Kumar Ghosh; Yashmin Choudhury
Journal:  J Pharmacol Toxicol Methods       Date:  2016-10-20       Impact factor: 1.950

4.  Simple screening tests for peripheral neuropathy in the diabetes clinic.

Authors:  B A Perkins; D Olaleye; B Zinman; V Bril
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

5.  The use of animal models in diabetes research.

Authors:  Aileen J F King
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

6.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

Review 7.  Criteria for creating and assessing mouse models of diabetic neuropathy.

Authors:  Kelli A Sullivan; Stephen I Lentz; John L Roberts; Eva L Feldman
Journal:  Curr Drug Targets       Date:  2008-01       Impact factor: 3.465

8.  Cycloart-23-ene-3β, 25-diol stimulates GLP-1 (7-36) amide secretion in streptozotocin-nicotinamide induced diabetic Sprague Dawley rats: a mechanistic approach.

Authors:  Sachin L Badole; Sagar P Mahamuni; Pranita P Bagul; Rekha D Khose; Anuja C Joshi; Arvindkumar E Ghule; Subhash L Bodhankar; Chandrashekhar G Raut; Vijay M Khedkar; Evans C Coutinho; Nilesh K Wagh
Journal:  Eur J Pharmacol       Date:  2012-10-29       Impact factor: 4.432

9.  A Dual Noradrenergic Mechanism for the Relief of Neuropathic Allodynia by the Antidepressant Drugs Duloxetine and Amitriptyline.

Authors:  Mélanie Kremer; Ipek Yalcin; Yannick Goumon; Xavier Wurtz; Laurent Nexon; Dorothée Daniel; Salim Megat; Rhian A Ceredig; Carl Ernst; Gustavo Turecki; Virginie Chavant; Jean-François Théroux; Adrien Lacaud; Lauriane-Elisabeth Joganah; Vincent Lelievre; Dominique Massotte; Pierre-Eric Lutz; Ralf Gilsbach; Eric Salvat; Michel Barrot
Journal:  J Neurosci       Date:  2018-09-24       Impact factor: 6.167

10.  Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications.

Authors:  David André Barrière; Christophe Noll; Geneviève Roussy; Farah Lizotte; Anissa Kessai; Karyn Kirby; Karine Belleville; Nicolas Beaudet; Jean-Michel Longpré; André C Carpentier; Pedro Geraldes; Philippe Sarret
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.